Multiple Endocrine Neoplasia Type 2 Syndrome

1. Al-Ravi M, Wheeler MH. Medullary thyroid carcinoma – update and present management controversies. Ann R Coll Engl 2006; 88: 433–438.

2. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005; 16: 441–467.

3. Arighi E, Popsueva A, Degl‘Innocenti D et al. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung‘s disease. Mol Endocrinol 2004; 18: 1004–1017.

4. Asai N, Jijiwa M, Enomoto A et al. RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung’s disease. Pathol Int 2006; 56: 164–172.

5. Bendlová B, Dvořáková Š, Václavíková E et al. Nádory štítné žlázy a Hirschsprungova choroba: desetileté zkušenosti s molekulárně genetickou diagnostikou RET proto-onkogenu. Vnitř Lék 2006; 52(10): 609–617.

6. Bendlová B, Jindřichová Š, Vlček P. RET proto-onkogen v patogenezi nádorů štítné žlázy, syndromů MEN 2 a Hirschsprungovy choroby. Česko-slovenská pediatrie 2003; 58(6): 343–350.

7. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658–5671.

8. Bugalho MJ, Domingues R, Sobrinho L. Molecular diagnosis of multiple endocrine neoplasia Type 2. Expert Rev Mol Diagn 2003; 3: 769–779.

9. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003; 253: 616–626.

10. Da Silva AM, Maciel RM, Da Silva MR et al. A novel germ‑line point mutation in RET exon 8 (Gly(553)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 5438–5443.

11. de Groot JWB, Links TP, Plukker JTM et al. RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary endocrine tumors. Endocrine Rev 2006; 27: 535–560.

12. Donis-Keller H, Dou S, Ch D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851–856.

13. Dvorakova S, Dvorakova K, Malikova M et al. A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung‘s disease. J Pediatr Surg 2005; 40: e1–6.

14. Dvorakova S, Vaclavikova E, Duskova J et al. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ‑line mutation Gly321Arg. J Endocrinol Invest 2005; 28: 905–909.

15. Dvorakova S, Vaclavikova E, Duskova J et al. Exon 5 of the RET proto-oncogene – a newly detected risk exon for Familial Medullary Thyroid Carcinoma – a novel germ‑line mutation Gly321Arg. J Endocrin Invest 2005; 28(10): 905–909.

16. Dvorakova S, Vaclavikova E, Ryska A et al. Double germline mutations in the RET proto-oncogene in MEN 2A and MEN 2B kindreds. Exp Clin Endocrinol Diabetes 2006; 114: 192–196.

17. Dvorakova S, Vaclavikova E, Sykorova V et al. New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma. Thyroid 2006; 16(3): 311–316.

18. Dvorakova S, Vaclavikova E, Sykorova V et al. Somatic Mutations in the RET proto-oncogene in Sporadic Medullary Thyroid Carcinomas. Mol Cell Endocrinol 2008; 284(1–2): 21–27.

19. Dvořáková Š, Dvořáková K, Malíková M et al. A Novel Czech Kindred With Familial Medullary Thyroid Carcinoma and Hirschsprung’s Disease. J Ped Surg 2005; 40: E1–E6.

20. Eng C, Clayton D, Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276: 1575–1579.

21. Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 1997; 9: 97–109.

22. Fitze G, Schierz M, Bredow J et al. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 2002; 236: 570–575.

23. Guyétant S, Bléchet C, Saint-Adré JP. C-cell hyperplasia. Ann Endocrinol 2006; 67: 190–197.

24. Hofstra RM, Landsvater RM, Ceccherini I et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375–376.

25. Holub V, Dvořáková Š, Václavíková E et al. Význam molekulárně genetického vyšetření u syndromu mnohočetné endokrinní neoplázie typu 2A na příkladu jedné rodiny o třech generacích. Prakt Lék 2007; 87(3): 157–159.

26. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Letters 2004; 204: 197–211.

27. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene 2000; 19: 5590–5597.

28. Jimenez C, Habra MA, Juany SC et al. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab 2004; 89: 4142–4145.

29. Jindřichová Š, Kodet R, Krsková L et al. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Molecular Medicine 2003; 81(12): 819–823.

30. Jindřichová Š, Včelák J, Vlček P et al. Screening of Six Risk Exons of the RET proto-oncogene in Families with Medullary Thyroid Carcinoma in the Czech Republic. J Endocrinology 2004; 183: 257–265.

31. Jindřichová Š, Vlček P, Bendlová B. Medulární karcinom štítné žlázy – molekulárně genetický screening. Lékařské listy 2006; 19: 9–11.

32. Jindřichová Š, Vlček P, Bendlová B. Genetické příčiny vzniku karcinomů štítné žlázy. ČLČ 2004; 10: 664–668.

33. Kahraman T, de Groot JW, Rouwe C et al. Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a. Eur J Surg Oncol 2003; 29: 331–335.

34. Kouvaraki MA, Shapiro SE, Perrier ND et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005; 15: 531–544.

35. Lakhani VP, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med 2007; 58: 253–265.

36. Lips CJ, Hoppener JW, Van Nesselrooij BP et al. Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelines. J Intern Med 2005; 257: 69–77.

37. Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: From bedside to bench to bedside. Mol Cell Endocrinol 2006; 247: 34–40.

38. Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progression of hereditary Medullary Thyroid Cancer. N Engl J Med 2003; 349: 1517–1525.

39. Machens A, Ukkat J, Brauckhoff M et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005; 257: 50–59.

40. Maruna P, Dušková J, Límanová Z et al. Mixed medullary and follicular cell carcinoma of the thyroid in 71-year-old man. A case report. Med Sci Monit 2007; 14(4): CS31–CS36.

41. Mulligan LM, Kwok JB, Healey CS et al. Germ‑line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458–460.

42. Multiple Endocrine Neoplasia Type 2. Gene Reviews – NCBI Bookshelf. Dostupné z http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=men2.

43. Neradilová M, Bendlová B, Němec J. Genetické endokrinopatie – medulární karcinom. Lékařské Listy 1997; 46(37): 13.

44. Neradilová M, Bendlová B. Medulární karcinom štítné žlázy – přehled 20letých zkušeností. Diabetologie, metabolismus, endokrinologie, výživa 2000; 2(3): 33–41.

45. Romeo G, Ceccherini I, Celli J et al. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 1998; 243: 515–520.

46. Ryška A, Čáp J, Václavíková E et al. Paraganglioma‑like medullary thyroid carcinoma: fine needle aspiration cytology features with histological correlation. Cytopathology 2008; 9 (Epub ahead of print).

47. Santoro M, Melillo RM, Carlomagno F et al. Minireview: RET: normal and abnormal functions. Endocrinology 2004; 145: 5448–5451.

48. Simon S, Pavel M, Hensen J et al. Multiple endocrine neoplasia 2A syndrome: Surgical management. J Pediatr Surg 2002; 37: 897–900.

49. Skinner MA, Moley JA, Dilley WG et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Eng J Med 2005; 353: 1105–1113.

50. Sýkorová V, Dvořáková Š, Kodetová D et al. Genetické příčiny vzniku papilárního karcinomu štítné žlázy. DMEV 2007; 10(1): 30–35.

51. Szinnai G, Meier C, Komminoth P et al. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 2003; 111: E132–E139.

52. Škába R, Dvořáková Š, Václavíková E et al. The risk of medullary thyroid carcinoma in patients with Hirschsprung’s disease. Pediatr Surg Int 2006; 22(12): 991–995.

53. Takahashi M, Iwashita T, Santoro M et al. Co-segregation of MEN2 and Hirschsprung‘s disease: the same mutation of RET with both gain and loss-of-function? Hum Mutat 1999; 13: 331–336.

54. Vlček P, Neumann J. Karcinom štítné žlázy. Pooperační sledování nemocných. 1. vyd. Praha: Maxdorf 2002: 220. ISBN: 80-85912-50-3.

55. Vlček P. Nádory štítné žlázy. In: Límanová Z. Štítná žláza. Trendy soudobé endokrinologie. Sv. 2. Praha: Galen 2006: 299–315.

56. Yip L, Cote GJ, Shapiro SE et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003; 138: 409–416.